Autres langues Attana AB

Actions

ATANA

SE0010547273

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 00:00:00 07/05/2024			Varia. 5j.	Varia. 1 janv.
0,082 ^SEK	-3,53%		+1,23%	-17,17%

30/04	BioInvent annonce l'évaluation de la technologie d'Attana	CI
25/04	Attana AB entre dans la troisième année d'un contrat de service et de soutien de cinq ans avec un institut de santé de premier plan aux États-Unis	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioInvent evaluating Attana Technology	30/04
BioInvent Announces Evaluating Attana Technology	30/04
Attana enters the third year of a five-year service and support contract with a leading health institute in the US	25/04
Attana AB Enters Third Year of A Five-Year Service and Support Contract with A Leading Health Institute in the US	25/04
New paper using Attana tecnology to understand how viruses enter human cells	01/04
One of US leading health institutes has placed an order for an upgrade of an existing instrument, valued at $150k	05/03
Attana AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/02
New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.	13/02
New publication using Attana technology towards environmentally friendly and financially viable methods to create functional materials	23/01
New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases	20/12
Biosensors to characterize immune response to bacterial diseases	18/12
Attana and Linnaeus University have published the first part of the science behind immunity profiles	05/12
Attana Lands Order for Kinetic Interaction Analysis of Tissue in US	04/12
Breakthrough order with new customer in the USA	04/12
Attana AB Receives Breakthrough Order with New Customer in the USA	04/12
Strengthened collaboration with European biotech customer who extends their service and support agreement for another 12 months.	23/11
Customer Develops Therapeutic Antibodies Against Cancer and Uses Attana's Cell-Based Technology	23/11
A new publication using Attana Technology from National University of Singapore examining the neutralization capacity of human IgG antibodies agsinst different mutations of the SARS-CoV-2	20/11
Robust QCM-Based Sensing and Assay Formats in Commercialized Systems	15/11
Attana AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	26/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Attana AB

Actions

ATANA

SE0010547273

Autres langues

Filtres